HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.2
  1. Home
  2. /Compound

Triflusal

HCID 9458
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
322-79-2
Standard SMILES
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
InChIKey
RMWVZGDJPAKBDE-UHFFFAOYSA-N
Molecular formula
C10H7F3O4
Average molar mass
248.15 g/mol
Monoisotopic mass
248.02964319

Overview

2-acetyloxy-4-(trifluoromethyl)benzoic acid is a member of benzoic acids, a member of salicylates and a carboxylic ester.

Names & identifiers

Preferred name
Triflusal
IUPAC
2-acetyloxy-4-(trifluoromethyl)benzoic acid
English name
Triflusal
Molecular formula
C10H7F3O4
Molecular weight
248.16

Names & synonyms

Triflusal322-79-22-Acetoxy-4-trifluoromethylbenzoic acid2-(Acetyloxy)-4-(trifluoromethyl)benzoic acidTriflusalumDTXSID80453051Z0YFI05OODTXCID6025305RefChem:191611B01AC18206-297-5Disgren
Show more names
ur1501DrisgenTriflusal-d3Triflusal CRSTriflusal (UR1501)TRIFLUOROTRIMESICACIDTriflusal, 10 mM in DMSO4-trifluoromethylsalicylicacidacetate
2-Acetoxy-4-(trifluoromethyl)benzoic Acid2-acetyloxy-4-(trifluoromethyl)benzoic acidAflenTriflusal [INN]MFCD00866793TrifluxBenzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)-Prestwick1_000528

Database identifiers

CAS
322-79-2
PubChem CID
9458
DTXSID
DTXSID8045305
ChEMBL
CHEMBL1332032
ChEBI
CHEBI:94721
UNII
1Z0YFI05OO
EC Number
206-297-5
Nikkaji
J5.672C

Properties

Computed structural properties

XLogP
2.1
Topological polar surface area
63.6 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
7
Rotatable bonds
3
Heavy atoms
17
Formal charge
0
Complexity
313

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Blood and blood forming organs -> Antithrombotic agents

Solubility<1 mg/ml
Melting Point114-117ºC

Physicochemical properties

Melting point
120 · 120-122° (upon slow heating); 110-112° (upon quick heating)
Boiling point
316 · 316.0±42.0 °C(Predicted)
Density
1.433 · 1.433±0.06 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
solubility
30 mg/mL · DMSO: >30mg/mL
pka
2.97 · 2.97±0.10(Predicted)
form
powder
color
white to off-white
λmax
297 nm · 297nm(H2O)(lit.)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Safety data

wgk
3
rtecs
GP4250000
hs_code
2918.29.7500
risk_code
22-36/37/38-43
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xn
safety_code
26-36/37
Storage Class
11 - Combustible Solids
target organs
Respiratory system
Hazard statements
H302-H315-H317-H319-H335
Hazard Classifications
Acute Tox. 4 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1STOT SE 3
Precautionary statements
P261-P264-P280-P304+P340+P312-P333+P313

Chemistry & industry

Pharmacology

ATC Code · 2 items

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein BindingTriflusal binds almost completely to plasma proteins reaching a 99% of the administered dose.
Pharmacodynamics · 1 item

Triflusal is an antithrombotic anticoagulant. It irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Triflusal affects many other targets such as NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. Numerous studies comparing the efficacy and safety profile (i.e. systemic hemorrhage) between triflusal and acetylsalsylic acid has shown either no significant difference or a better effacy and safety profile for triflusal. Triflusal has been shown to protect cerebral tissue due to its inhibition of lipid peroxidation resulting from anoxia-reoxygenation.

Mechanism of Action · 1 item

Triflusal is chemically related to acetylsalicylic acid (ASA) and irreversibly inhibits cycloxygenase-1 (COX-1) in platelets. Acetylation of the active group of COX-1 prevents the formation of thromboxane-B2 in platelets. However, it is unique because it spares the arachidonic acid metabolic pathway in endothelial cells. In addition, it favors the production of nitric oxide, a vasodilator.

Biological Half-LifeIn the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.
Metabolism/MetabolitesIn the liver, triflusal undergoes deacetylation, forming its main metabolite 2-OH-4-trifluoromethyl benzoic acid (HTB). This major metabolite seems to have marked antiplatelet properties in vitro.
MeSH Pharmacological Classification · 1 item

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Related reactions

2 records
New reaction record
HRID 98027 reaction equation
HRID 98027As reactant
HRID 1038770 reaction equation
HRID 1038770As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Merck
14 · 14,9688
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
InChIKey
RMWVZGDJPAKBDE-UHFFFAOYSA-N
SMILES
FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
CAS DataBase Reference
322 · 322-79-2(CAS DataBase Reference)
FDA UNII
1 Z0YFI05OO · 1Z0YFI05OO
ATC code
1 AC18 · B01AC18
Comptox DTXSID
8045305 · DTXSID8045305
UNSPSC Code
41116107 · 41116107
NACRES
25 · NA.25
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H317-H319-H335
Precautionary statements
261 · P261-P264-P280-P304+P340+P312-P333+P313
target organs
Respiratory system
Hazard Codes
Xn
Risk Statements
22 · 22-36/37/38-43
Safety Statements
26 · 26-36/37
WGK Germany
3 · 3
RTECS
4250000 · GP4250000
HS Code
2918.29 · 2918.29.7500
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralEye · Acute Tox. 4 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1STOT SE 3
Absorption, Distribution and Excretion · 4 items

Absorbed in the small intestine with a bioavailability range from 83% to 100%. There is no significant difference between the absorption of the oral solution and capsule formulation. Triflusal displays a Cmax of 11.6 mcg/ml and a tmax of 0.88 h. The major metabolite of triflusal presents different pharmacokinetic properties by showing a Cmax and tmax of 92.7 mcg/ml and 4.96 h, respectively.

The elimination pathway of triflusal is primarily renal. Urine analysis has shown the presence of unchanged triflusal, HTB and the glycine conjugate of HTB.

The reported volume of distribution for triflusal is of 34L.

Renal clearance is 0.8 +/- 0.2L/h and 0.18 +/1 0.04L/h for triflusal and HTB, respectively.

Applications · 3 items

DescriptionTriflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specic inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of Triflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, Triflusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of Triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).

UsesAn analog of Aspirin; inhibits platelet aggregation. Antithrombotic.

UsesAntithrombotic;Cyclooxygenase inhibitor

Upstream & downstream products

Downstream products

acetate4-Trifluoromethylsalicylic acid

Additional notes

DefinitionChEBI: 2-acetyloxy-4-(trifluoromethyl)benzoic acid is a member of salicylates, a carboxylic ester and a member of benzoic acids.